1. Home
  2. ZSTK vs CTXR Comparison

ZSTK vs CTXR Comparison

Compare ZSTK & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZSTK

ZeroStack Corp. Common Stock

N/A

Current Price

$5.30

Market Cap

20.0M

Sector

Health Care

ML Signal

N/A

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.69

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZSTK
CTXR
Founded
2019
2007
Country
Canada
United States
Employees
76
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.0M
18.9M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
ZSTK
CTXR
Price
$5.30
$0.69
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
8.8K
759.8K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.38
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.73
N/A
Revenue Next Year
N/A
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.76
$0.57
52 Week High
$11.00
$2.38

Technical Indicators

Market Signals
Indicator
ZSTK
CTXR
Relative Strength Index (RSI) 37.54 43.05
Support Level $4.76 $0.68
Resistance Level $9.65 $0.99
Average True Range (ATR) 0.69 0.07
MACD -0.07 -0.02
Stochastic Oscillator 0.84 26.76

Price Performance

Historical Comparison
ZSTK
CTXR

About ZSTK ZeroStack Corp. Common Stock

ZeroStack Corp is an AI focused asset management company. The company also operates a world-wide pharmaceutical distribution business through its wholly owned subsidiary. ZeroStack is focused on providing exposure to decentralized AI through a concentrated digital asset approach structured to generate yield and fee-based income from staking validators, compute power technology companies, and complementary businesses within the ecosystem and across the wider AI landscape.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: